Date updated:02-23-2008
Summary of the bullish and bearish positions mentioned in the February 23rd, 2007 Barron's.

-
ANF
Abercrombie & Fit - $32.44
- -2.23%
- $33.20
The company's stock could top $100 within a year, climbing by a third. Abercrombie's new Gilly Hicks lingerie chain looks promising, joining the hugely popular Hollister.

-
CELG
Celgene Corporati - $54.77
- -0.71%
- $N/A
Celgene's earnings-growth pace could keep rising -- to 50% -- on more drug triumphs, as could the high (some say too high) 24 multiple on its stock. But at 54 now, it may be worth 20% more.

-
ZURN.VX
Zurich Finl Svcs - $240.00
- +1.14%
- $239.00
If Zurich Financial Services stays on course to deliver strong earnings and high returns on equity, its shares, now 317 Swiss francs, could rally 25% or more.

-
MRVL
Marvell Technolog - $18.07
- -0.55%
- $18.24
Marvell shares could double in two years if it fixes its options mess, controls costs and gets a 3G-capable chip to market.

-
DIS
Walt Disney-disne - $29.48
- -0.20%
- $29.76
For the price of a Disney share, too, an investor effectively buys access to a braintrust probably unrivaled in American business. Apple's Steve Jobs, a Pixar founder, is Disney's largest shareholder, with 7% of the float. Fellow owner Warren Buffett no doubt picks up the phone for Iger. Procter & Gamble's former CEO, John Pepper, with all the consumer-product knowledge one could want, chairs Disney's board.

-
CROX
Crocs - $7.11
- +2.75%
- $6.97
We're neutral now, and think investors should cover their short positions and take a walk. The stock sells today for only nine times analysts' '08 earnings estimate of around $2.70 a share, and the shoes are still the rage among soccer moms and nurses, suggesting the stock might not drop much lower from here, at least in the near term.

-
WYE
- $48.54
- 0.00%
- $N/A
In her estimation, Wyeth's stock price suggests that investors do not appreciate the value of these assets. At $40, Rubin contends, investors are effectively "getting the pipeline for free." Her analysis suggests that Wyeth's vaccines, biologics (biotechnology drugs) and OTC assets are worth about $35, or about 90% of the stock price. By 2012, Rubin expects biologics and vaccines to account for about 70% of Wyeth's earnings. She raised her investment rating on the stock to Overweight from Equal Weight, and upped her one-year price target to $48 from $46.
- Barron's Summary 02-23-2008's Blog
- No Blogs Found
- Top Professional Portfolios
- 1. Fidelity Contrafund - ...
- 2. Bernard L. Madoff Inve...
- 3. Argus Management
- 4. Calamos Advisors
- 5. Charlie Munger
- show all
- Top Do-It-Yourself Portfolios
- » jgroov Portfolio 1
- » ben johnson
- » my holdings
- » SC TRADE OF THE DAY
- » kudos
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Jonas Elmerraji Posted on Feb. 9, 2010 With stocks continuing to underwhelm in yesterday’s trading session, the attention is turning toward trading. After all, tec...
By Roberto Pedone Posted on Feb. 8, 2010 Good Buys For Bad Times: This Barron’s article says with the U.S. economy expected to grow by only 3% in 2010, investors shou...
Posted on Feb. 8, 2010 Finance Professor Scott Rothbort will be answering questions on Stockpickr Answers on Monday, Feb. 8. Ask away! Regardless of why a stock is in...
By Jonas Elmerraji Posted on Feb. 8, 2010 Finance Professor Scott Rothbort will be answering questions on Stockpickr Answers on Monday, Feb. 8. Ask away! Investor an...
A. The only one I own : SLX,
too hard pick a winner out all of them
TheStreet Ratings provides exclusive stock, ETF and mutual fund ratings and commentary based on award-winning, proprietary tools. Its safety first approach to investing aim... more
TheStreet Ratings provides exclusive stock, ETF and mutual fund ratings and commentary based on award-winning, proprietary tools. Its "safety first&quo... more
These are the stocks from Jim Cramer's Feb. 8 Lightning Round. We list the stocks on which he is BULLISH and BEARISH.... more











Comments not available